Kate Fife
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kate Fife has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
Amer Durrani
6 shared publications- Amit Roshan
Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK
6 shared publications Benjamin A. Hall
6 shared publications- Charlotte King
Wellcome Sanger Institute, Hinxton, UK
6 shared publications - Christopher Bryant
Wellcome Sanger Institute, Hinxton, United Kingdom
6 shared publications - David Fernandez-Antoran
University of Cambridge
6 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (22) , 2693-2708
A UK Delphi consensus study on the definition and management of advanced cutaneous squamous cell carcinoma
1. Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer in the United Kingdom (UK), and its incidence continues to rise each year [1,2]. When treated early, cSCC has a goo...
- 14 September 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (22) , 2693-2708
Open AccessA UK Delphi consensus study on the definition and management of advanced cutaneous squamous cell carcinoma
1. Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer in the United Kingdom (UK), and its incidence continues to rise each year [1,2]. When treated early, cSCC has a goo...
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (109)
Noncanonical Hedgehog signaling through Smoothened controls cytotoxic T cell migration in the tumor microenvironment
The Hedgehog (Hh) signaling pathway is aberrantly regulated in cancer. Hh inhibitors are successful in treating basal cell carcinoma (BCC) and Sonic Hedgehog–driven medulloblastoma but have largely failed in clinical trials of other solid cancers. We show that Hh inhibitor treatment specifically diminishes CD8 T cell migration into the tumor microenvironment, both in murine cancer models and resected BCCs from patients treated with the Smoothened (Smo) inhibitor vismodegib. Using small-molecule antagonists and genetic knockout models of key Hh signaling components, we demonstrate that the migration defect is mediated exclusively by the signal transducer Smo and not Hh ligands or Gli transcription factors. Smo acts noncanonically as a G protein–coupled receptor to regulate the migration of murine and human CD8 T cells via RhoA. Our data establish a link between Hh inhibition in vivo and the antitumor immune response and provide the basis for improved Hh targeting approaches for patients with cancer.
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (109)
Noncanonical Hedgehog signaling through Smoothened controls cytotoxic T cell migration in the tumor microenvironment
The Hedgehog (Hh) signaling pathway is aberrantly regulated in cancer. Hh inhibitors are successful in treating basal cell carcinoma (BCC) and Sonic Hedgehog–driven medulloblastoma but have largely failed in clinical trials of other solid cancers. We show that Hh inhibitor treatment specifically diminishes CD8 T cell migration into the tumor microenvironment, both in murine cancer models and resected BCCs from patients treated with the Smoothened (Smo) inhibitor vismodegib. Using small-molecule antagonists and genetic knockout models of key Hh signaling components, we demonstrate that the migration defect is mediated exclusively by the signal transducer Smo and not Hh ligands or Gli transcription factors. Smo acts noncanonically as a G protein–coupled receptor to regulate the migration of murine and human CD8 T cells via RhoA. Our data establish a link between Hh inhibition in vivo and the antitumor immune response and provide the basis for improved Hh targeting approaches for patients with cancer.
- 19 August 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (11) , e429-e438
Variability in Kidney Cancer Treatment and Survival in England: Results of a National Cohort Study
- 19 August 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (11) , e429-e438
Variability in Kidney Cancer Treatment and Survival in England: Results of a National Cohort Study
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Supplementary Figures S1-S7 and Tables S1 and S2
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Supplementary Figures S1-S7 and Tables S1 and S2
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Supplementary Figures S1-S7 and Tables S1 and S2
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Supplementary Figures S1-S7 and Tables S1 and S2
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Skin cancer risk varies substantially across the body, yet how this relates to the mutations found in normal skin is unknown. Here we mapped mutant clones in skin from high- and low-risk sites. The density of mutations varied by location. The prevalence of NOTCH1 and FAT1 mutations in forearm, trunk, and leg skin was similar to that in keratinocyte cancers. Most mutations were caused by ultraviolet light, but mutational signature analysis suggested differences in DNA-repair processes between sites. Eleven mutant genes were under positive selection, with TP53 preferentially selected in the head and FAT1 in the leg. Fine-scale mapping revealed 10% of clones had copy-number alterations. Analysis of hair follicles showed mutations in the upper follicle resembled adjacent skin, but the lower follicle was sparsely mutated. Normal skin is a dense patchwork of mutant clones arising from competitive selection that varies by location.Significance:Mapping mutant clones across the body reveals normal skin is a dense patchwork of mutant cells. The variation in cancer risk between sites substantially exceeds that in mutant clone density. More generally, mutant genes cannot be assigned as cancer drivers until their prevalence in normal tissue is known.See related commentary by De Dominici and DeGregori, p. 227.This article is highlighted in the In This Issue feature, p. 211
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Skin cancer risk varies substantially across the body, yet how this relates to the mutations found in normal skin is unknown. Here we mapped mutant clones in skin from high- and low-risk sites. The density of mutations varied by location. The prevalence of NOTCH1 and FAT1 mutations in forearm, trunk, and leg skin was similar to that in keratinocyte cancers. Most mutations were caused by ultraviolet light, but mutational signature analysis suggested differences in DNA-repair processes between sites. Eleven mutant genes were under positive selection, with TP53 preferentially selected in the head and FAT1 in the leg. Fine-scale mapping revealed 10% of clones had copy-number alterations. Analysis of hair follicles showed mutations in the upper follicle resembled adjacent skin, but the lower follicle was sparsely mutated. Normal skin is a dense patchwork of mutant clones arising from competitive selection that varies by location.Significance:Mapping mutant clones across the body reveals normal skin is a dense patchwork of mutant cells. The variation in cancer risk between sites substantially exceeds that in mutant clone density. More generally, mutant genes cannot be assigned as cancer drivers until their prevalence in normal tissue is known.See related commentary by De Dominici and DeGregori, p. 227.This article is highlighted in the In This Issue feature, p. 211
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
- Open Access
- 22 September 2021
- Published by Wiley in BJU International
- Vol. 130 (2) , 244-253
Dynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib
Objective: To explore translational biological and imaging biomarkers for sunitinib treatment before and after debulking nephrectomy in the NeoSun (European Union Drug Regulating Authorities Clinical Trials Database [EudraCT] number: 2005‐004502‐82) single‐centre, single‐arm, single‐agent, Phase II trial. Patients and Methods: Treatment‐naïve patients with metastatic renal cell carcinoma (mRCC) received 50 mg once daily sunitinib for 12 days pre‐surgically, then post‐surgery on 4 week‐on, 2 week‐off, repeating 6‐week cycles until disease progression in a single arm phase II trial. Structural and dynamic contrast‐enhanced magnet resonance imaging (DCE‐MRI) and research blood sampling were performed at baseline and after 12 days. Computed tomography imaging was performed at baseline and post‐surgery then every two cycles. The primary endpoint was objective response rate (Response Evaluation Criteria In Solid Tumors [RECIST]) excluding the resected kidney. Secondary endpoints included changes in DCE‐MRI of the tumour following pre‐surgery sunitinib, overall survival (OS), progression‐free survival (PFS), response duration, surgical morbidity/mortality, and toxicity. Translational and imaging endpoints were exploratory. Results: A total of 14 patients received pre‐surgery sunitinib, 71% (10/14) took the planned 12 doses. All underwent nephrectomy, and 13 recommenced sunitinib postoperatively. In all, 58.3% (seven of 12) of patients achieved partial or complete response (PR or CR) (95% confidence interval 27.7–84.8%). The median OS was 33.7 months and median PFS was 15.7 months. Amongst those achieving a PR or CR, the median response duration was 8.7 months. No unexpected surgical complications, sunitinib‐related toxicities, or surgical delays occurred. Within the translational endpoints, pre‐surgical sunitinib significantly increased necrosis, and reduced cluster of differentiation‐31 (CD31), Ki67, circulating vascular endothelial growth factor‐C (VEGF‐C), and transfer constant ( K Trans , measured using DCE‐MRI; all P < 0.05). There was a trend for improved OS in patients with high baseline plasma VEGF‐C expression ( P = 0.02). Reduction in radiological tumour volume after pre‐surgical sunitinib correlated with high percentage of solid tumour components at baseline (Spearman’s coefficient ρ = 0.69, P = 0.02). Conversely, the percentage tumour volume reduction correlated with lower baseline percentage necrosis (coefficient = −0.51, P = 0.03). Conclusion: Neoadjuvant studies such as the NeoSun can safely and effectively explore translational biological and imaging endpoints.
- 22 September 2021
- Published by Wiley in BJU International
- Vol. 130 (2) , 244-253
Open AccessDynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib
Objective: To explore translational biological and imaging biomarkers for sunitinib treatment before and after debulking nephrectomy in the NeoSun (European Union Drug Regulating Authorities Clinical Trials Database [EudraCT] number: 2005‐004502‐82) single‐centre, single‐arm, single‐agent, Phase II trial. Patients and Methods: Treatment‐naïve patients with metastatic renal cell carcinoma (mRCC) received 50 mg once daily sunitinib for 12 days pre‐surgically, then post‐surgery on 4 week‐on, 2 week‐off, repeating 6‐week cycles until disease progression in a single arm phase II trial. Structural and dynamic contrast‐enhanced magnet resonance imaging (DCE‐MRI) and research blood sampling were performed at baseline and after 12 days. Computed tomography imaging was performed at baseline and post‐surgery then every two cycles. The primary endpoint was objective response rate (Response Evaluation Criteria In Solid Tumors [RECIST]) excluding the resected kidney. Secondary endpoints included changes in DCE‐MRI of the tumour following pre‐surgery sunitinib, overall survival (OS), progression‐free survival (PFS), response duration, surgical morbidity/mortality, and toxicity. Translational and imaging endpoints were exploratory. Results: A total of 14 patients received pre‐surgery sunitinib, 71% (10/14) took the planned 12 doses. All underwent nephrectomy, and 13 recommenced sunitinib postoperatively. In all, 58.3% (seven of 12) of patients achieved partial or complete response (PR or CR) (95% confidence interval 27.7–84.8%). The median OS was 33.7 months and median PFS was 15.7 months. Amongst those achieving a PR or CR, the median response duration was 8.7 months. No unexpected surgical complications, sunitinib‐related toxicities, or surgical delays occurred. Within the translational endpoints, pre‐surgical sunitinib significantly increased necrosis, and reduced cluster of differentiation‐31 (CD31), Ki67, circulating vascular endothelial growth factor‐C (VEGF‐C), and transfer constant ( K Trans , measured using DCE‐MRI; all P < 0.05). There was a trend for improved OS in patients with high baseline plasma VEGF‐C expression ( P = 0.02). Reduction in radiological tumour volume after pre‐surgical sunitinib correlated with high percentage of solid tumour components at baseline (Spearman’s coefficient ρ = 0.69, P = 0.02). Conversely, the percentage tumour volume reduction correlated with lower baseline percentage necrosis (coefficient = −0.51, P = 0.03). Conclusion: Neoadjuvant studies such as the NeoSun can safely and effectively explore translational biological and imaging endpoints.
- 11 August 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (30) , 3905-3909
What is the Role of Real-World Data in Metastatic Renal Cell Cancer?
- 11 August 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (30) , 3905-3909
What is the Role of Real-World Data in Metastatic Renal Cell Cancer?